{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:31:08Z","timestamp":1787923868943,"version":"build-2784847793"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jval.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:25:47Z","timestamp":1786033547000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reframing NICE\u2019s Cost-Effectiveness Threshold: Technical Benchmark or Policy Signal? A Documentary Content Analysis"],"prefix":"10.1016","author":[{"given":"Hesam","family":"Ghiasvand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyran","family":"Naghdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2026.07.004_bib2","first-page":"391","article-title":"UK-US pharmaceutical deal: NHS will pay billions more for new drugs","author":"Wise","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2026.07.004_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r2622","article-title":"Ministers seek power to control NHS drug approvals to support Us Pharma deal","volume":"391","author":"Mahase","year":"2025","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jval.2026.07.004_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hec.864","article-title":"Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis","volume":"13","author":"Devlin","year":"2004","journal-title":"Health Econ"},{"issue":"7459","key":"10.1016\/j.jval.2026.07.004_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.329.7459.224","article-title":"National Institute for Clinical Excellence and its value judgments","volume":"329","author":"Rawlins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2026.07.004_bib6","series-title":"International cost-effectiveness thresholds and modifiers for HTA decision making","author":"Zhang","year":"2020"},{"issue":"1","key":"10.1016\/j.jval.2026.07.004_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1258\/135581907779497567","article-title":"Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence","volume":"12","author":"Culyer","year":"2007","journal-title":"J Health Serv Res Policy"},{"issue":"5","key":"10.1016\/j.jval.2026.07.004_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40258-022-00730-3","article-title":"Supply-side cost-effectiveness thresholds: questions for evidence-based policy","volume":"20","author":"Sampson","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"10.1016\/j.jval.2026.07.004_bib9","first-page":"1162","article-title":"HTA\u2019d in the USA: a comparison of ICER in the United States with NICE in England and Wales","volume":"26","author":"Thokala","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.jval.2026.07.004_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10728-019-00381-x","article-title":"NICE and fair? Health technology assessment policy under the UK\u2019s National Institute for Health and Care Excellence, 1999-2018","volume":"28","author":"Charlton","year":"2020","journal-title":"Health Care Anal"},{"issue":"14","key":"10.1016\/j.jval.2026.07.004_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol Assess"},{"issue":"5","key":"10.1016\/j.jval.2026.07.004_bib12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jval.2020.11.015","article-title":"10 years of end-of-life criteria in the United Kingdom","volume":"24","author":"Bovenberg","year":"2021","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.07.004_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jval.2024.02.013","article-title":"Understanding the National Institute for Health and Care Excellence severity premium: exploring its implementation and implications for decision making and patient access","volume":"27","author":"Njoroge","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.07.004_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40273-025-01579-9","article-title":"Economic consequences of increasing the NICE cost-effectiveness threshold","volume":"44","author":"Paulden","year":"2026","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2026.07.004_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40258-025-01026-y","article-title":"Politicised changes to the NICE threshold risk making cost-effectiveness analysis performative, not informative","volume":"24","author":"Vallejo-Torres","year":"2026","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"10.1016\/j.jval.2026.07.004_bib16","doi-asserted-by":"crossref","first-page":"e3977","DOI":"10.1111\/hsc.13791","article-title":"Conceptualisation of health inequalities by local healthcare systems: a document analysis","volume":"30","author":"Olivera","year":"2022","journal-title":"Health Soc Care Community"},{"issue":"10","key":"10.1016\/j.jval.2026.07.004_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-102163","article-title":"From action policy: a document content analysis reviewing the adoption of the healthcare inequalities programme in local health system plans in England","volume":"15","author":"Elliott","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2026.07.004_bib18","series-title":"Qualitative Research in Health Care","first-page":"83","article-title":"Documentary analysis","author":"Gorsky","year":"2020"},{"issue":"10","key":"10.1016\/j.jval.2026.07.004_bib19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/heapol\/czaa064","article-title":"Document analysis in health policy research: the READ approach","volume":"35","author":"Dalglish","year":"2020","journal-title":"Health Policy Plan"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:54:59Z","timestamp":1787921699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"alternative-id":["S1098301526025672"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.07.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reframing NICE\u2019s Cost-Effectiveness Threshold: Technical Benchmark or Policy Signal? A Documentary Content Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}